About UsAbout UsServicesProductsNews & EventsContact Us
About Us

Services

ProductsPublicationsTestimonials

News & Events

Contact Us

A Strategic Assessment of Infectious Disease Innovations

The objective of this report, issued June 1999, is to identify, critique, and rate emerging infectious disease products available for in-licensing. The analyses are current and discriminating - both the merits and the pitfalls of each product have been stringently reviewed against a number of relevant criteria embracing both product (e.g., mode of action) and company source (e.g., management, pipeline). In the final analysis, readers will be uniquely positioned to act quickly on expanding or launching their infectious disease product line.

Table of Contents

List of Figures and Tables
Preface
Expert Contributors
I. Action Report
II. Executive Summary
III. Introduction
IV. Market Dynamics
V. Report Methodology

Infectious Diseases

VI. Infectious Disease and Chronic Sequelae
VII. Antibiotic Resistance
VIII. Cytomegalo Virus
IX. Fungal Infections
X. Hepatitis B
XI. Hepatitis C
XII. Human Immunodeficiency Virus
XIII. Human Papilloma Virus
XIV. Influenza
XV. Parainfluenza and Respiratory Syncytial Viruses
XVI. Tuberculosis

Platforms

XVII. Immunotherapy (HBV and HCV)
XVIII. Nucleoside Analogs (HBV and HIV)
XIX. Inosine Monophosphate Dehydrogenase (IMPDH) inhibitors (HBV)
XX. Non-Nucleoside Reverse Transcriptase Inhibitors (HIV)
XXI. HIV-1 Fusion Inhibitors (HIV)
XXII. HIV-1 Viral Resistance Assays
XXIII. Nucleoside Analog Reverse Transcriptase Inhibitors (HIV)
XXIV. Human Papilloma Virus Vaccine
XXV. Antimicrobial Peptides
XXVI. Monoclonal Antibody Therapy (CMV)
XXVII. Parainfluenza Virus Vaccine
XXVIII. Antifungal Peptides
XXIX. Conclusion

Infectious Disease Panelists

Joan E. Kapusnik-Uner, Pharm.D.
Senior Knowledge Engineer
First DataBank, Inc.

Theo N. Kirkland III, M.D.
Professor of Pathology and Medicine
Infectious Disease Section
University of California, San Diego

Dimitrios P. Kontoyiannis, M.D.
Assistant Professor of Medicine
The University of Texas
MD Anderson Cancer Center

Leigh Stone
Managing Director/Partner
Ferghana Partners Group

John B. Wright
President
Lifetime Learning, Inc.

Infectious Disease Editorial Board

Joshua Fierer, M.D.
Head, Division of Infectious Diseases
University of California, San Diego

Keith A. Joiner, M.D.
Associate Chairman, Department of Medicine
Director, Investigative Medicine Program
Yale University

William A. Petri, M.D., Ph.D.
Professor of Internal Medicine, Pathology and Microbiology
Division of Infectious Diseases
University of Virginia

For pricing information and instructions on how to order this publication, [click here - link to auto-calculate form].
© 2017 BeckerPharmaceuticals. All Rights Reserved.